U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H4NO2.Zn
Molecular Weight 309.612
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC PICOLINATE

SMILES

[Zn++].[O-]C(=O)C1=CC=CC=N1.[O-]C(=O)C2=CC=CC=N2

InChI

InChIKey=NHVUUBRKFZWXRN-UHFFFAOYSA-L
InChI=1S/2C6H5NO2.Zn/c2*8-6(9)5-3-1-2-4-7-5;/h2*1-4H,(H,8,9);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H4NO2
Molecular Weight 122.1015
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
2002 Mar 1
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
[Reduced thymulin production during occupational exposure to lead].
2005 Jan-Mar
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:26:45 UTC 2023
Edited
by admin
on Fri Dec 15 16:26:45 UTC 2023
Record UNII
ALO92O31SE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC PICOLINATE
INCI   WHO-DD  
INCI  
Official Name English
ZINC PICOLINATE [INCI]
Common Name English
2-PYRIDINECARBOXYLIC ACID, ZINC COMPLEX
Common Name English
Zinc picolinate [WHO-DD]
Common Name English
Classification Tree Code System Code
DSLD 2939 (Number of products:7)
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
Code System Code Type Description
SMS_ID
100000126049
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
FDA UNII
ALO92O31SE
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
WIKIPEDIA
Zinc picolinate
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
EVMPD
SUB32915
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
MESH
C030614
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
DRUG BANK
DB11175
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
NCI_THESAURUS
C87350
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
EPA CompTox
DTXSID60170814
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
CAS
17949-65-4
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
DAILYMED
ALO92O31SE
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
CONCEPT Dietary Supplement
RXCUI
58301
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY RxNorm
PUBCHEM
9904746
Created by admin on Fri Dec 15 16:26:45 UTC 2023 , Edited by admin on Fri Dec 15 16:26:45 UTC 2023
PRIMARY
Related Record Type Details
Structure of PICOLINIC ACID
PARENT -> SALT/SOLVATE
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966